Cardiovascular Therapy and Prevention (Russian Federation) · Published 2026-04-29 · DOI 10.15829/1728-8800-2026-4514
Aim. To identify the optimal combination of cardiovascular toxicity (CVT) markers for subsequent optimization of the diagnosis of cardiovascular adverse events in patients with non-Hodgkin lymphomas.Material and methods. This prospective study was conducted to monitor cardiovascular adverse events in patients treated with the R-CHOP regimen. A total of 116 patients were divided into main (n=58, mean age 55,4±12,4 years, 25 (43,1%) men) and control groups (n=58, mean age 54,9±11,4 years, 32 (55,1%) men). Division of patients into subgroups was carried out taking into account CVT: A1 and B1 — with CVT: A1 — 21 patients, 55,9±11,17 years, 15 men (71,4%); B1 — 10 patients, 56,75±9,11 years, 6 men (60%); A2 — 37 patients, 55,16±13,12 years, 13 men (35,1%); B2 — 48 patients, mean age 54,24±12,18 years, men n=28 (58,3%).Results. CVT was more common in men (p=0,039, pA1-A2=0,008, pA2-B2=0,031) and smokers (p=0,026, pA1-A2=0,04, pA2-B2=0,046, pA2-B1=0,004). The level of N-terminal pro-brain natriuretic peptide (NT-proBNP) significantly increased from 86,50 (68,50;113,50) to 150,50 (71,00;372,50) pg/ml (p=0,023, pV2-V3=0,026) in the target group of patients. Among patients with CVT, a longer QTc was recorded, as well as a lower level of global longitudinal systolic strain (p=0,008, Visit 2, p=0,003, Visit 3).Conclusion. The mathematical model developed by the authors, based on paraclinical parameters and allowing for CVT diagnosis optimization, is proposed for use in real-world practice.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →